While some physicians are prescribing these medications for their approved uses of treating type 2 diabetes, obesity and obstructive sleep apnea, others are frequently making off-label prescriptions
Say goodbye to ineffective diet fads and tiresome workout regimes, and say hello to a groundbreaking solution Semaglutide
Fatigue from glucose highs and lows: sugary snacks create unstable energy levels and increase tiredness
Call your insurance provider to ask what documentation they require, then work with your doctor to submit a prior authorization with supporting records like lab work, chart notes and evidence of prior lifestyle changes
GLP-1 Game-Changer: How Oral GLP-1s Will Shape Health Plan Strategy Authored by Leslie Lotano-Saba GLP-1s for diabetes and obesity are already a top concern of health plan CEOs, with the category forecasted to achieve 13% to 15% CAGR growth from 2024 to 2034, reaching approximately $130 billion in total market size